Exclusive: Onyx provides drug trial data to potential bidders – sources

By Soyoung Kim and Deena Beasley (Reuters) – Onyx Pharmaceuticals Inc has given potential buyers, including Amgen Inc, access to trial data on its new cancer drug, removing a key hurdle that was holding up deal talks, according to three people familiar with the matter. The company’s attempt to sell itself for around $9.5 billion hit an impasse in recent weeks after lead bidder Amgen sought trial data about blood cancer drug Kyprolis – something that Onyx was reluctant to share, Reuters reported last week. …